secwatch.observer — SEC 8-K summary ====================================== Issuer: Tempest Therapeutics, Inc. (TPST) CIK: 0001544227 Form: 8-K Filed at: 2026-11-20T21:05:27+00:00 Accession: 0001213900-26-122694 Event type: regulatory Sentiment: negative Materiality: 0.85 Item codes: 3.01 LLM model: deepseek-v4.1-flash:cloud@v2 Tempest Therapeutics hit with Nasdaq delisting notice after missing $2.5M equity compliance extension -------------------------------------------------------------------------------- - Nov 17, 2026: Nasdaq Staff issued delisting notification, saying Tempest did not meet terms of the extension granted Oct 30, 2026 (deadline Nov 16, 2026). - Company failed to complete a capital raising transaction needed to regain compliance with Nasdaq Listing Rule 5550(b)(1), the $2.5M minimum stockholders' equity rule. - Root cause: stockholders' equity below $2.5 million as reported in the Form 10-Q for the quarter ended March 31, 2026; original notice received May 19, 2026. - Tempest will appeal via a Rule 5815 oral hearing request, which stays suspension/delisting; shares continue trading on the Nasdaq Capital Market meanwhile. - Hearings typically occur 30-45 days after the request, with a panel decision usually within 30 days; company gives no assurance the appeal succeeds. Source: EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000121390026122694/0001213900-26-122694-index.htm Primary doc: https://www.sec.gov/Archives/edgar/data/1544227/000121390026122694/ea0313132-8k_tempest.htm HTML page: https://secwatch.observer/filing/0001213900-26-122694 License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer